報價延遲最少15分鐘:2025/08/31 08:10 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.77 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-76.90/-17.70
|
|
企業價值
12.84M
|
| 資產負債 |
|
每股賬面淨值
7.07
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/31 08:10 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers. |
